Improvements Across Measures of Behavior, Function, Cognition and Movement -- Expediting Plans to Advance CT1812 into Late-Stage Trials -- Full ...

“Lewy body dementia can be caused by a condition called ‘dementia with Lewy bodies’ (DLB), where a certain protein builds up ...

Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...

B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up ...

and movement measures in patients with dementia with Lewy bodies (DLB). “The results from this exploratory Phase 2 trial demonstrated CT1812 could have a meaningful, positive impact on DLB ...

Researchers have combined two sequencing technologies in single cells to find new differences in mRNAs resulting from Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease.

Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body ...